Polymorphisms in xenobiotic conjugation and disease predisposition.

Area of Science:

• Molecular epidemiology
• Cancer research
• Genetics

Background:

• Slow arylamine N-acetyltransferase 2 (NAT2) activity is linked to urinary bladder cancer.
• Gene-environment and gene-gene interactions modify this risk.
• Glutathione S-transferase M1 deficiency (GSTM1*0/0) is a recognized metabolic susceptibility factor for several cancers.

Purpose of the Study:

• To investigate the role of NAT2, NAT1, CYP1A2, and GSTM1 genotypes in urinary bladder cancer risk.
• To explore gene-environment and gene-gene interactions in bladder cancer etiology.
• To discuss methodological considerations for molecular epidemiological studies.

Main Methods:

• Analysis of arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genotypes.
• Assessment of cytochrome P450 1A2 (CYP1A2) polymorphisms.
• Evaluation of glutathione S-transferase M1 (GSTM1) deficiency.
• Consideration of gene-environment (smoking) and gene-gene interactions.

Main Results:

• Slow NAT2 genotype significantly increases bladder cancer risk, particularly in smokers (OR=2.7).
• NAT1*10 allele showed only moderate activity and was underrepresented in bladder cancer.
• CYP1A2 high inducibility variant was associated with bladder cancer in smokers with slow NAT2.
• GSTM1*0/0 is a moderate risk factor, potentially dominant with specific gene combinations or exposures.

Conclusions:

• Slow NAT2 is a significant risk factor for urinary bladder cancer, amplified by smoking.
• GSTM1*0/0 is a well-established metabolic susceptibility factor.
• Molecular epidemiology is crucial for understanding complex carcinogenesis and personalizing cancer prevention.